Bevacizumab Biosimilar

DRUG8 trials

Conditions

Advanced Hepatocellular Carcinoma (HCC)Breast CancerColon AdenocarcinomaColorectal Cancer MetastaticHepatocellular CarcinomaHepatocellular Carcinoma (HCC)Rectal Adenocarcinoma

Phase 1

Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC

NCT04843943

Fudan UniversityHepatocellular Carcinoma

Start: 2021-05-01End: 2023-05-01Target: 30Updated: 2021-04-14

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

RecruitingNCT06530251

AkesoHepatocellular Carcinoma

Start: 2024-09-24End: 2028-09-01Target: 280Updated: 2026-03-04

Phase 2

HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC

NCT05029973

Tianjin Medical University Cancer Institute and HospitalHepatocellular Carcinoma

Start: 2021-05-10End: 2023-11-10Target: 30Updated: 2023-02-08

Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC

NCT05386524

Fudan UniversityBreast Cancer

Start: 2022-06-15End: 2025-03-15Target: 41Updated: 2023-02-16

HAIC Combined with Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)

RecruitingNCT06860490

Fudan UniversityHepatocellular Carcinoma (HCC)

Start: 2025-03-18End: 2028-03-10Target: 164Updated: 2025-03-26

Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）

Not yet recruitingNCT07007767

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyColorectal Cancer Metastatic

Start: 2025-06-15End: 2027-12-30Target: 32Updated: 2025-06-06

Phase 3

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

RecruitingNCT06997497

Merck Sharp & Dohme LLCColon Adenocarcinoma, Rectal Adenocarcinoma

Start: 2025-07-16End: 2030-10-27Target: 477Updated: 2026-04-03

Unknown Phase

Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

Not yet recruitingNCT07147101

Fudan UniversityAdvanced Hepatocellular Carcinoma (HCC)

Start: 2025-09-01End: 2028-09-01Target: 150Updated: 2025-08-28

Journal of Clinical Oncology2026-01-10

Sintilimab plus bevacizumab followed by resection in intermediate-stage hepatocellular carcinoma: a phase Ib clinical trial with biomarker analysis

BMJ Oncology2024-12-012 citations

Hepatic artery infusion chemotherapy (HAIC) plus sintilimab and bevacizumab biosimilar (IBI305) in initial unresectable hepatocellular carcinoma (HCC): A retrospective study.

Journal of Clinical Oncology2024-06-01

Sintilimab combined with bevacizumab biosimilar as a conversion therapy in potentially resectable intermediate-stage hepatocellular carcinoma (HCC): Updated results of a phase II trial.

Journal of Clinical Oncology2023-06-016 citations

Hepatic artery infusion chemotherapy (HAIC) combined with sintilimab and bevacizumab biosimilar (IBI305) for initial unresectable hepatocellular carcinoma (HCC): A prospective, single-arm phase II trial.

Journal of Clinical Oncology2022-06-0117 citations